For example, EphB4 has been identified as a predictive biomarker for the therapy response of colorectal cancer patients receiving the vascular endothelial growth factor (VEGF)-targeting antibody bevacizumab, with an increased EphB4 expression in non-responders [6]. This evidence concerns the gene VEGFA and colorectal cancer.